iRadimed (NASDAQ:IRMD) Releases FY 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.060-2.210 for the period, compared to the consensus estimate of 2.040. The company issued revenue guidance of $91.0 million-$96.0 million, compared to the consensus revenue estimate of $91.0 million. iRadimed also updated its Q1 2026 guidance to 0.440-0.480 EPS.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on IRMD. Roth Mkm set a $90.00 target price on shares of iRadimed in a research note on Friday, October 31st. Lake Street Capital reissued a “buy” rating and issued a $100.00 price target on shares of iRadimed in a research note on Monday, November 3rd. Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Finally, Zacks Research upgraded shares of iRadimed to a “hold” rating in a report on Tuesday, November 4th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $95.00.

iRadimed Trading Up 9.4%

iRadimed stock traded up $8.98 on Tuesday, hitting $104.95. 26,731 shares of the stock traded hands, compared to its average volume of 74,355. iRadimed has a 1 year low of $47.48 and a 1 year high of $107.90. The firm has a market cap of $1.33 billion, a P/E ratio of 63.60 and a beta of 1.11. The business’s fifty day simple moving average is $97.82 and its 200 day simple moving average is $83.09.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.05. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The company had revenue of $22.69 million during the quarter, compared to analyst estimates of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, analysts predict that iRadimed will post 1.66 earnings per share for the current year.

iRadimed Dividend Announcement

The business also recently declared a special dividend, which was paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th were paid a $0.50 dividend. The ex-dividend date was Wednesday, December 17th. iRadimed’s dividend payout ratio is presently 41.21%.

Insiders Place Their Bets

In other news, CEO Roger E. Susi sold 5,000 shares of iRadimed stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $100.65, for a total value of $503,250.00. Following the completion of the transaction, the chief executive officer owned 2,262,500 shares of the company’s stock, valued at $227,720,625. The trade was a 0.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO John Glenn sold 15,000 shares of the stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the sale, the chief financial officer directly owned 7,362 shares in the company, valued at $716,248.98. This trade represents a 67.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 55,000 shares of company stock valued at $5,287,900 in the last quarter. 36.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On iRadimed

Several institutional investors and hedge funds have recently made changes to their positions in IRMD. Algert Global LLC boosted its position in shares of iRadimed by 87.5% during the third quarter. Algert Global LLC now owns 50,797 shares of the medical equipment provider’s stock valued at $3,615,000 after buying an additional 23,710 shares during the last quarter. UBS Group AG raised its stake in shares of iRadimed by 389.9% in the third quarter. UBS Group AG now owns 25,433 shares of the medical equipment provider’s stock worth $1,810,000 after buying an additional 20,242 shares during the period. Punch & Associates Investment Management Inc. purchased a new stake in iRadimed in the 3rd quarter worth approximately $1,210,000. Two Sigma Investments LP lifted its stake in shares of iRadimed by 33.4% during the 3rd quarter. Two Sigma Investments LP now owns 53,647 shares of the medical equipment provider’s stock valued at $3,818,000 after buying an additional 13,417 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its position in shares of iRadimed by 8,568.5% during the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock worth $591,000 after purchasing an additional 11,139 shares in the last quarter. Institutional investors own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.